U.S., Dec. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07269080) titled 'STM-06: POLARIS-POlymetastic Lesion Ablative Radiotherapy With Immunotherapy Study' on Nov. 21.
Brief Summary: This is a non-randomized two-arm trial, specifically a pilot study in which patients with advanced solid tumor cancer with 3-10 metastatic lesions who are on immunotherapy will receive ablative RT to up to 10 lesions. After study intervention, participants will undergo ctDNA collection at 8 weeks after completion of ablative RT Post-treatment disease assessments, including imaging and serial ctDNA monitoring, as well as any additional treatments, will be at the discretion of the treating oncologist. Approximately 28 subjects...